Skip to main content

Public Policy

By Susan Morse | 02:02 pm | February 25, 2026
A strong MFN law could be a meaningful step toward bringing U.S. prices in line with those paid by other high-income countries, says Patients for Affordable Drugs Now.
By HIMSS TV | 10:19 am | February 25, 2026
Ovatient CEO Michael Dalton recommends that states use Rural Health Transformation Program money to move beyond hospital-centric care models and supplement local health services with virtual-first primary and specialty care.
By Jessica Hagen | 03:53 pm | February 20, 2026
Ryan M. Harrison of the CDC joins MobiHealthNews to preview his upcoming HIMSS26 talk where he'll discuss how the agency’s Technical Reference Architecture accelerates digital transformation across federal public health systems.
By Susan Morse | 01:34 pm | February 16, 2026
Revenue growth will come from clinical outcomes versus document mechanics, says Steve Mongelli, president at mPulse.
By Jessica Hagen | 11:15 am | February 13, 2026
The plans are committing to adopt value-driven payment structures that expand tech-enabled care for Medicare beneficiaries with chronic conditions.
By Susan Morse | 11:48 am | February 09, 2026
HHS is looking at how the care plan is supporting the patient, says Sandy Griffiths, senior product manager for Homecare Homebase.
By Jessica Hagen | 03:37 pm | February 06, 2026
A federal jury found that Medtronic, which plans to appeal the ruling, unlawfully monopolized the bipolar surgical device market through anticompetitive bundling and exclusive-deal practices that harmed rival Applied Medical.
By Susan Morse | 02:26 pm | February 04, 2026
The minibus package also funds HHS and extends acute hospital care at home.
By Andrea Fox | 04:08 pm | January 30, 2026
"It's a positive moment," says Kyle Zebley, ATA's CEO and executive director of ATA Action, in a conversation about health tech policy advances and the organization's strategies for 2026.
By HIMSS TV | 10:43 am | January 16, 2026
Michael Abrams of Numerof and Associates says that oversight for AI used in mental health care should mirror that of pharmaceuticals, with clear standards, safety testing and ongoing monitoring.